Cost Effectiveness of Dolutegravir as a First-Line Treatment Option in the HIV-1–Infected Treatment-Naive Patients in Russia

ConclusionsWith lower costs, higher response rates, and comparable QALYs, DTG + ABC/3TC can be considered as a cost-effective alternative.

Source: Value in Health Regional Issues - October 5, 2018 Category: International Medicine & Public Health Source Type: research